21 studies found for:    TRC105
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
2 Active, not recruiting Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
3 Recruiting A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Condition: Advanced Soft Tissue Sarcoma
Intervention: Drug: TRC105 and Pazopanib
4 Recruiting Trial of TRC105 and Sorafenib in Patients With HCC
Condition: Hepatocellular Carcinoma
Interventions: Drug: TRC105;   Drug: Sorafenib
5 Recruiting Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Conditions: Gestational Trophoblastic Neoplasia;   Choriocarcinoma;   Placental Site Trophoblastic Tumor;   Epithelioid Trophoblastic Tumor
Interventions: Drug: TRC105;   Drug: Bevacizumab
6 Enrolling by invitation An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy
Condition: Solid Tumors
Interventions: Drug: TRC105;   Drug: Bevacizumab;   Drug: Axitinib;   Drug: Pazopanib;   Drug: Capecitabine
7 Enrolling by invitation Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Condition: Choriocarcinoma
Interventions: Biological: TRC105;   Biological: Bevacizumab
8 Completed
Has Results
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention: Drug: TRC105
9 Recruiting A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: TRC105
10 Terminated
Has Results
TRC105 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: TRC105
11 Completed Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Recurrent Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
12 Completed
Has Results
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Conditions: Urothelial Carcinoma;   Ureteral Neoplasms;   Ureter Cancer;   Neoplasm, Ureteral;   Cancer of the Ureter
Intervention: Drug: TRC105
13 Recruiting A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: TRC105 and Axitinib
14 Not yet recruiting A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA
Condition: Advanced Angiosarcoma
Interventions: Biological: TRC105;   Drug: Votrient
15 Completed
Has Results
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
16 Completed Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
Conditions: Cancer;   Neoplasm Metastasis
Intervention: Drug: TRC105 chimeric anti-CD105 antibody
17 Recruiting Sorafenib and TRC105 in Hepatocellular Cancer
Conditions: Hepatoma;   Liver Neoplasms;   Adenoma, Liver Cell;   Carcinoma, Hepatocellular;   Liver Neoplasms, Experimental
Interventions: Drug: TRC 105;   Drug: Sorafenib
18 Active, not recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Neoplasm
Interventions: Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
19 Active, not recruiting Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Active, not recruiting A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
Conditions: Glioblastoma;   Glioblastoma Multiforme
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.